PURE Key Statistics, Chart & Performance
The current stock price of PURE is 0.37 null. In the past month the price decreased by -36.21%. In the past year, price increased by 48%.
PURE Technical Analysis
PURE Financial Highlights
Over the last trailing twelve months PURE reported a non-GAAP Earnings per Share(EPS) of -0.08. The EPS increased by 27.27% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -277.17% | ||
| ROA | -74.9% | ||
| ROE | -125.22% | ||
| Debt/Equity | 0 |
PURE Forecast & Estimates
PURE Ownership
About PURE
Company Profile
PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including methicillin-resistant Staphylococcus aureus (MRSA), or staph infection. PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of `green` products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it.
Company Info
Pure Bioscience
1725 GILLESPIE WAY
EL CAJON CA 92020
CEO: Henry R. Lambert
Phone: 619-596-8600
Pure Bioscience / PURE FAQ
What does PURE do?
PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including methicillin-resistant Staphylococcus aureus (MRSA), or staph infection. PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of `green` products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it.
What is the current price of PURE stock?
The current stock price of PURE is 0.37 null. The price decreased by -15.91% in the last trading session.
Does PURE stock pay dividends?
PURE does not pay a dividend.
What is the ChartMill technical and fundamental rating of PURE stock?
PURE has a ChartMill Technical rating of 0 out of 10.You can find more details on the Technical Analysis and Fundamental Analysis tabs.
How is the valuation of Pure Bioscience (PURE) based on its PE ratio?
Pure Bioscience (PURE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.08).
Can you provide the upcoming earnings date for Pure Bioscience?
Pure Bioscience (PURE) will report earnings on 2022-03-14, after the market close.